skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: your thoughts on Sanara MedTech
thanks again
Read Answer Asked by George on January 23, 2023
Q: Moving past the opioid settlement, is this name worth revisiting? I have not owned in years, debt appears better but still high. Is there a better play on pharmaceuticals for an aging population.
Read Answer Asked by Jim on January 17, 2023
Q: Your advices to hold on to the above stocks for January bounce is correct so far. When will the bounce normally ends? When it ends,is it time to sell OR should ask the question then? Well had a huge increase of 15 94% to $3.71 today.Please comment as I cannot find any news. Thanks for U usual great services & views
Read Answer Asked by Peter on January 17, 2023
Q: The market seems to like the news but I would appreciate your views on their just released Q1 results. I realize that they still came in at a loss but that was solely attributable to an increase in operating costs (specifically R&D and a ramp up of its US sales force in advance of the release of SavvyWire). I remain surprised that we're still trading below their recent financing level. Thanks as always.
Read Answer Asked by karl on January 16, 2023
Q: We often see conflicting analyst opinions, but ratings of MDT seem to be on one extreme or other. For what it’s worth, MDT appears on various lists of “best stocks for 2023”. And just this week, Barrons carried this story: “ Buy Medtronic Stock. Shares of the Dividend Aristocrat Look Attractive” (January 2). This morning RBC-DI downgraded MDT from outperform while CFRA maintains a Buy. Both RBC-DI and CFRA seem to reasonably good track records. I have held MDT shares from multi-year highs all the way down to today’s miserable level. (Tax loss not useable).

I have previously asked you about MDT and possibly others here may have done so too. Would you care to take a side in this frustrating debate with your reasons? Thanks.

Read Answer Asked by Adam on January 10, 2023
Q: Could you provide any information/prospects on the above stock? Thanks.
Read Answer Asked by Michael on January 10, 2023
Q: Asked by Doris on January 09, 2023
5I RESEARCH ANSWER:
We are not big fans of the staples sector overall right now in the US. It has fared decently over the last year but valuations are at the higher end now, as growth should moderate alongside inflation. Also, now that bonds offer more attractive yields, we think the relative attractiveness of staples is lower than it was a year ago (more safe alternatives for stability and yield now).

We think it is difficult to be too hard on COST though. Overall, we think staples names in Canada look a bit more attractive due to what looks like lower valuations on average. In Canada, we think PBH, ATD and NWC are worth looking at.

this is an answer you gave regarding staples . would you feel the same eay about hwalthcare stocks, such as gilead, etc
Read Answer Asked by joseph on January 10, 2023